Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas.

Brain tumor pathology - 1 Jul 2015

Takano Shingo, Kato Yukinari, Yamamoto Tetsuya, Liu Xing, Ishikawa Eiichi, Kaneko Mika K, Ogasawara Satoshi, Matsuda Masahide, Noguchi Masayuki, Matsumura Akira

Abstract excerpt

Isocitrate dehydrogenase (IDH) mutation is a valuable prognostic marker and a tool for decision-making for glioma treatment. An algorithm for IDH mutation screening was recently proposed--it consists of a two-step process of an initial search for the most common IDH1-R132H mutation using immunohistochemistry (IHC)-based assay, followed by DNA-based analysis of IHC-negative or -equivocal cases. Here, we report...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Glioma

Share to Immunohistochemistry

Share to Isocitrate Dehydrogenase

Share to Neoplasm Staging

Share to Prognosis

Source

Identifiers

PMID: 25652153
DOI: 10.1007/s10014-015-0214-8

Genes

IDH1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Diagnostic advantage of double immunohistochemistry using two mutation-specific anti-IDH antibodies (HMab-1 and MsMab-1) in gliomas.PMID 25652153Read ↗

Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain ReactionSemantic proximity Read ↗

Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas.Semantic proximity Read ↗

IDH mutation analysis in gliomas as a diagnostic and prognostic biomarker.Semantic proximity Read ↗

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.Semantic proximity Read ↗

IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee.Semantic proximity Read ↗

Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.Semantic proximity Read ↗

Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.Semantic proximity Read ↗

Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors.Semantic proximity Read ↗

Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.Semantic proximity Read ↗

Concordance analysis and diagnostic test accuracy review of IDH1 immunohistochemistry in glioblastoma.Semantic proximity Read ↗

Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations.Semantic proximity Read ↗

Monoclonal antibody specific for IDH1 R132H mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.